LAVAL, Quebec, Dec. 7, 2017 /CNW/ -- Valeant Pharmaceuticals
International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today
announced that Scott A. Hirsch,
senior vice president and chief business strategy officer, and
Arthur J. Shannon, senior vice
president and head of Investor Relations and Communications, are
scheduled to participate at the BMO Capital Markets 2017
Prescriptions for Success Healthcare Conference in New York on Dec. 14,
2017 at 2:00 p.m. EST.
A live webcast and audio archive of the event will be available
on the Investor Relations page of the Valeant web site at:
http://ir.valeant.com/events-and-presentations/2017.
About Valeant
Valeant Pharmaceuticals International,
Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical
company that develops, manufactures and markets a broad range of
pharmaceutical products primarily in the areas of dermatology,
gastrointestinal disorders, eye health, neurology and branded
generics. More information about Valeant can be found at
www.valeant.com.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@valeant.com
|
lainie.keller@valeant.com
|
(514)
856-3855
|
(908)
927-0617
|
(877) 281-6642 (toll
free)
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/valeant-to-participate-at-the-bmo-capital-markets-2017-prescriptions-for-success-healthcare-conference-300567761.html
SOURCE Valeant Pharmaceuticals International, Inc.